At a glance
- Originator Bristol-Myers Squibb
- Class Antibacterials; Naphthyridines; Quinolones
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 10 Jan 2001 No-Development-Reported for Bacterial infections in USA (Unknown route)
- 01 May 1995 New profile